Diltiazem

Diltiazem is a calcium channel blocker taken by mouth. The US label read, for Cardizem, lists one use: the management of chronic stable angina and angina due to coronary artery spasm. Cardizem CD and Cardizem LA are separate extended-release products with their own labels, which were not read.

Also called Cardizem · Diltiazem hydrochloride

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 3443; UNII OLH94387TE. The label names the substance as diltiazem hydrochloride, so UNII OLH94387TE is the UNII of the salt form and is a broad match. MeSH descriptor D004110 is Diltiazem. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the CARDIZEM (diltiazem hydrochloride) tablets, Bausch Health US LLC label, effective 2025-04-30 in openFDA (application NDA018602). Other diltiazem labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 6 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
6
Phase 3 or 4
5
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseNot yet recruitingEnrolling by invitationCompletedUnknown statusAll statuses
Phase 1/200101
Phase 411125
All phases11226

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 1 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII OLH94387TE

Claims and evidence

Context People for whom the US label of diltiazem (Cardizem) lists an indication: chronic stable angina, angina due to coronary artery spasm

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with chronic stable angina
  • Patients with angina due to coronary artery spasm
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of CARDIZEM (diltiazem hydrochloride), in the Bausch Health US LLC version dated 2025-04-30 in openFDA, lists the medicine for the management of chronic stable angina and angina due to coronary artery spasm.

    Applies to Recipient not specified People for whom the US label of diltiazem (Cardizem) lists an indication: chronic stable angina, angina due to coronary artery spasm

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for CARDIZEM (diltiazem hydrochloride) tablets, Bausch Health US LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f3e7ecef-f360-4987-a4f5-933214130ab2 (manufacturer Bausch Health US LLC, application NDA018602), returned on 2026-11-09. The label text is dated 2025-04-30 (effective_time). Other openFDA records of diltiazem labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-04-30
      Source state
      Current
      Version fingerprint
      31d00490399711edd34a07a6130c2ebbb66e5d41bbddddf7b5da4f66b78e7d14
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for CARDIZEM (diltiazem hydrochloride) tablets, Bausch Health US LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f3e7ecef-f360-4987-a4f5-933214130ab2 (manufacturer Bausch Health US LLC, application NDA018602), returned on 2026-11-09. The label text is dated 2025-04-30 (effective_time). Other openFDA records of diltiazem labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250430.
      Retrieved
      Source effective date
      2025-04-30
      Source state
      Current
      Version fingerprint
      31d00490399711edd34a07a6130c2ebbb66e5d41bbddddf7b5da4f66b78e7d14
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

CARDIZEM

No label from the application holder was found in the openFDA label dataset for application NDA018602. This page does not show another labeler's label in its place.

CARDIZEM

No label from the application holder was found in the openFDA label dataset for application NDA020027. This page does not show another labeler's label in its place.

CARDIZEM

No label from the application holder was found in the openFDA label dataset for application NDA020792. This page does not show another labeler's label in its place.

CARDIZEM CD

No label from the application holder was found in the openFDA label dataset for application NDA020062. This page does not show another labeler's label in its place.

CARDIZEM LA

No label from the application holder was found in the openFDA label dataset for application NDA021392. This page does not show another labeler's label in its place.

CARDIZEM SR

No label from the application holder was found in the openFDA label dataset for application NDA019471. This page does not show another labeler's label in its place.

DILACOR XR

No label from the application holder was found in the openFDA label dataset for application NDA020092. This page does not show another labeler's label in its place.

DILTIAZEM HYDROCHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA020939. This page does not show another labeler's label in its place.

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

No label from the application holder was found in the openFDA label dataset for application NDA218038. This page does not show another labeler's label in its place.

DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

No label from the application holder was found in the openFDA label dataset for application NDA215252. This page does not show another labeler's label in its place.

TIAZAC

No label from the application holder was found in the openFDA label dataset for application NDA020401. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA018602 CARDIZEM
  2. Supplemental approval NDA018602 CARDIZEM
  3. Supplemental approval NDA018602 CARDIZEM
  4. Approval NDA019471 CARDIZEM SR
  5. Approval NDA020027 CARDIZEM
  6. Approval NDA020062 CARDIZEM CD
  7. Approval NDA020092 DILACOR XR
  8. Supplemental approval NDA020062 CARDIZEM CD
  9. Supplemental approval NDA020062 CARDIZEM CD
  10. Supplemental approval NDA018602 CARDIZEM
  11. Supplemental approval NDA020092 DILACOR XR
  12. Approval NDA020401 TIAZAC
  13. Approval NDA020792 CARDIZEM
  14. Supplemental approval NDA020401 TIAZAC
  15. Approval NDA020939 DILTIAZEM HYDROCHLORIDE
  16. Approval NDA021392 CARDIZEM LA
  17. Supplemental approval NDA021392 CARDIZEM LA
  18. Approval NDA215252 DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%
  19. Approval NDA218038 DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 11

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA018602

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019471

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020027

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA020062

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA020092

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA020401

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020792

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020939

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA021392

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA215252

Registry trials 6

Record details

Record id
cardio:diltiazem
Content hash
a3ca390ad26d314abaedccd7a409bef33efd7cb4dd2743cff527c823d4c39537